Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
218.82
-5.29 (-2.36%)
At close: Jun 1, 2026, 4:00 PM EDT
218.82
0.00 (0.00%)
After-hours: Jun 1, 2026, 4:15 PM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $298.54. The average 1-year stock price forecast is 36.43% higher than the current stock price, while the lowest is $253.66 (+15.92%) and the highest is $355.72 (+62.56%).
Price Target: $298.54 (+36.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 |
|---|---|---|
| Strong Buy | 3 | 13 |
| Buy | 1 | 4 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 4 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Buy Maintains $295 | Buy | Maintains | $295 | +34.81% | May 20, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $256 → $241 | Buy | Maintains | $256 → $241 | +9.91% | May 18, 2026 |
| Evercore ISI | Evercore ISI | Buy Reiterates $324 → $329 | Buy | Reiterates | $324 → $329 | +50.35% | May 15, 2026 |
Unknown Analyst Citi No rating | Citi | Buy Initiates $355 | Buy | Initiates | $355 | +62.23% | May 15, 2026 |
| Barclays | Barclays | Buy Reiterates $342 → $345 | Buy | Reiterates | $342 → $345 | +57.66% | May 11, 2026 |
Financial Forecast
Revenue This Year
1.39B
from 720.13M
Increased by 92.88%
Revenue Next Year
2.00B
from 1.39B
Increased by 44.20%
EPS This Year
12.42
from -3.76
EPS Next Year
9.85
from 12.42
Decreased by -20.66%
Financial currency is EUR.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.6B | 2.4B | ||||||
| Avg | 1.4B | 2.0B | ||||||
| Low | 1.2B | 1.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 126.1% | 73.7% | ||||||
| Avg | 92.9% | 44.2% | ||||||
| Low | 71.5% | 23.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 16.25 | 15.91 | |
| Avg | 12.42 | 9.85 | |
| Low | 4.00 | 5.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 28.1% | |
| Avg | - | -20.7% | |
| Low | - | -56.5% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.